Apply our platforms, OS-T and OS-IP, to vaccine development, therapy response, disease reccurence, and more.
Identify publicly conserved clonotypes, measure their activation and efficiency against disease and analyze to which epitopes it has been most commonly associated.
For more information, watch the longitudinal COVID-19 case study by Dr. Christian Brander of IrsiCaixa and discover how OS-T can accelerate your vaccine development.
Powered by
and
Track immune response for immunotherapy success.
Powered by
and
Sensitive quantification of Minimal Residual Disease (MRD) for haematological malignancies at high resolution from blood.
Powered by
and
Identify publicly conserved clonotypes, measure their activation and efficiency against disease and analyze to which epitopes it has been most commonly associated.
Powered by
and
Track immune response for immunotherapy success.
Powered by
and
Sensitive quantification of Minimal Residual Disease (MRD) at high resolution from blood.
Powered by
and